← Back to patent-cliff list
18F-BMS-986229
Tier C — Watch / trade18F-BMS-986229
Bristol-Myers Squibb International Corp
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
In vivo diagnostic
Type
Targets：PD-L1
Indications (approved)：Non-small cell lung cancer, Oesophageal cancer, Gastric cancer, Adenocarcinoma
Regional status
US
Phase II
2018-07-12
EU
Phase II
2018-07-12
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of 18F-BMS-986229?
Approved indications include: Non-small cell lung cancer, Oesophageal cancer, Gastric cancer, Adenocarcinoma.
When does the 18F-BMS-986229 patent expire?
No public expiry year is available for 18F-BMS-986229 yet; this page updates once verified.
How do I get a quote for 18F-BMS-986229 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08